Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives by Bede, Peter et al.
Palliative care in amyotrophic lateral sclerosis:
a review of current international guidelines
and initiatives
Peter Bede,1 David Oliver,2,3 James Stodart,4 Leonard van den Berg,5
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ABSTRACT
Background Amyotrophic lateral sclerosis (ALS) is
a relentlessly progressive neurodegenerative condition.
Optimal management requires a palliative approach from
diagnosis with emphasis on patient autonomy, dignity
and quality of life.
Objective To conduct a systematic analysis of the type,
level and timing of specialist palliative care intervention
in ALS.
Results Despite an international consensus that ALS
management should adopt a multidisciplinary approach,
integration of palliative care into ALS management varies
considerably across health care systems. Late referral to
palliative services in ALS is not uncommon and may
impact negatively on the quality of life of ALS patients
and their caregivers. However, common themes and
principles of engagement can be identified across
different jurisdictions, and measurement systems have
been established that can assess the impact of palliative
care intervention.
Conclusions There is considerable evidence that
palliative care intervention improves quality of life in
patients and carers. International consensus guidelines
would assist in the development of a framework for
active palliative care engagement in ALS and other
neurodegenerative diseases.
INTRODUCTION
Expansion of palliative care into non-malignant
conditions has contributed to improvements in
quality of life, symptom control and caregiver
burden in neurodegenerative conditions such as
amyotrophic lateral sclerosis (ALS).1 The point at
which referral to palliative services occurs varies
considerably across different countries. Early
involvement and a dynamic model of intervention
have been repeatedly suggested for ALS but few
countries have developed integrated pathways of
care. The objective of this review is to identify and
examine the existing guidelines for palliative care in
ALS, focusing on time of referral, triggers of referral
and coordination of care.
METHODS
Publications were searched during a 4 month period
between April 2010 and July 2010. Only articles
published in English were reviewed. Further articles
were identified through reviews of the references of
these articles. Reports from meetings were also
used if they presented relevant information.
The literature search was performed using
PubMed and Medline with the following keywords:
motor neuron disease (MND), amyotrophic lateral
sclerosis (ALS), neurodegenerative disorder, symp-
tomatic management, palliative care, guideline,
pathway, framework, policy and algorithm.
RESULTS
Palliative care in ALS
It is generally recognised that optimal ALS
management should adopt a multidisciplinary
approach that includes palliative care.2 There is
considerable evidence that multidisciplinary care
improves both survival and quality of life in ALS.3 4
It is also recognised that effective communication
between the multidisciplinary ALS team, the
primary care physician and the palliative care team
is essential, as patients with end stage ALS
frequently develop distressing symptoms over
a short period of time.5
Timing of specialist palliative care intervention
in ALS
The European Federation of Neurological Sciences
taskforce6 recommends that a palliative care
approach should be adopted from the time of
diagnosis and that palliative care should be avail-
able within the local community. Early referral to
palliative services in advance of the terminal phase
of ALS is recommended, as sufficient time is
required to establish relationships with the staff
and to address end of life issues. This is of particular
importance as speech and communication are often
limited in the later stages of disease.
In practice however, these recommendations are
rarely observed and there is currently no widely
accepted international standard for the initiation of
palliative care intervention. Management of the
terminal phase of ALS has been reported to be
unsatisfactory in 33% of cases in northern Europe
and in 61% of cases in southern Europe.7 In the UK,
only 30% of palliative units provide ALS care, and
only 8% are involved from the time of diagnosis.8
In the USA, stringent criteria are applied by
Medicare for access to hospice based palliative care.
The criteria include critically impaired breathing,
rapid progression and severe nutritional impair-
ment or rapid progression with life threatening
complications. These guidelines have been widely
criticised9 as many patients who do not meet the
Medicare hospice criteria die in less than 6 months.
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In one study,10 only five of 97 ALS patients who were accepted
into hospice care from a multidisciplinary ALS centre met the
Medicare criteria.
The US based ALS Peer Workgroup11 has suggested a number
of specific triggers for hospice referral of ALS patients (box 1).
Referral triggers tend to be based on the more typical symp-
toms of ALS, such as respiratory and nutritional compromise.
Rare, but distressing, complications of ALS such as severe pain of
uncertain aetiology, frozen shoulder and painful mouth ulcers
are frequently omitted from these guidelines, despite the fact
that palliative teams have considerable experience in alleviating
these symptoms.
Most ALS patients die at home. Where available, community
palliative care programmes can provide valuable home based
services and short term respite in the later stages of the disease.
These services are not ubiquitous, and many ALS patients have
no interaction with palliative services during their illness.12 In
a survey of 215 Irish patients with ALS, only 28% successfully
accessed palliative services.13 Perceived barriers to specialist
palliative management of patients with non-malignant and
neurodegenerative conditions include limited resources and lack
of familiarity of providers with the disease trajectory of ALS14
(box 2).
Other important differences across healthcare systems have
been noted in the management of ALS15 (table 1). These are
primarily a function of complex local financial, legal and cultural
factors.
There is evolving evidence that access to additional assistive
equipment might sometimes be limited once the patient is
formally receiving palliative care. Ideally, palliative care should
be integrated into the larger multidisciplinary care, and initia-
tion of hospice care should not limit availability of supportive
treatment such as gastrostomy and non-invasive ventilation.
End of life and advance directives
Advance directives provide patients with the option to exercise
autonomy regarding preferred end of life management strategies.
The legal validity of advance directives varies from country to
country.
Advance directives require a level of intellectual competence
that enables processing of relevant information and appreciation
of the consequences of decision making. Advance planning is
considered in three main formats: (a) an advance statement,
made by the person when still competent; (b) an advance
statement refusing treatmentdthis is legally binding in many
jurisdictions; and (c) a lasting power of attorney, which defines
a proxy to make decisions.
Advance directives are believed to be useful in 78% of Euro-
pean centres although only 30% of patients actually complete
them.7
Caregiver support
Effective palliative frameworks need to address caregiver needs.
There is evolving evidence that structured caregiver support,
including counselling, support groups and a crisis management
system, should be available for caregivers.16 Key barriers to
comprehensive carer support include the time constraints of
healthcare professionals and caregivers, lack of administrative
support, lack of trained personnel and financial barriers.17
Few studies have approached the optimal timing of hospice
referral from the carers’ point of view. A prospective interview
based study18 showed that the shorter the length of the stay in
a hospice, the more likely the families felt that enrolment to the
hospice had occurred too late.
Impact of cognitive and behavioural impairment on ALS
management
Up to 40% of patients with ALS have evidence of cognitive
impairment.19 20 Despite the published consensus criteria21 for
the diagnosis of cognitive and behavioural syndromes in ALS,
the practical application of the criteria can be problematic.
Formal neuropsychological testing may be particularly difficult
due to disease specific factors such as dysarthria, physical
disability, hypercapnia and medication effects. Currently,
different batteries of neuropsychological tests are used in
different centres. Most experts agree that a specialist clinical
neuropsychologist should be available as part of the multidisci-
plinary ALS team.22 Short cognitive screening tests have been
generated recently but have not yet been validated.23
Recognition of cognitive impairment is important because
survival is significantly shorter among ALS patients with
Box 1 Suggested triggers for hospice referral by the
Amyotrophic Lateral Sclerosis Peer Workgroup
1. Forced vital capacity (FVC): 60% predicted (or rapid decline in
FVC (more than 20%) over 2e3 months)
or
2. Clinical signs or clinical symptoms of respiratory insufficiency
or
3. Respiratory weakness requiring non-invasive positive pressure
ventilation
or
4. Nutritional decline requiring enteral feeding
or
5. Severe pain or psychosocial distress requiring intensive
palliative care interventions (including opioid medication)
or
6. Rapidly progressive paralysis (over 2e3 months) in two body
regions
Box 2 Key barriers to palliative care intervention in
non-malignant conditions in Ireland
1. Unpredictable non-cancer disease trajectory
2. Lack of defined referral criteria for non-malignant conditions
3. Lack of non-cancer disease specific expertise
4. Limited resources and high number of potential non-cancer
referrals
Table 1 Cross cultural differences in amyotrophic lateral sclerosis
management (Oliver et al15)
Medical and palliative intervention UK USA Japan
Gastrostomy 23% 50% 35%
Mean duration of gastrostomy feeding (months) 11 18 17
Non-invasive ventilation 13% 20% 36%
Mean duration of non-invasive ventilation (months) 10 5 5
Invasive ventilation 4% 0 9%
Mean duration of invasive ventilation (months) 10 0 80
End of life and advance directive discussions 23% 80% Not recorded
Timing of discussion (mean number of months
prior to death)
5 10
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frontotemporal dementia24 and ALS patients with executive
dysfunction (Elamin M, submitted 2011). Those with mild
cognitive changes are also less likely to choose long term
mechanical ventilation.25 Compliance with non-invasive venti-
lation is adversely affected by cognitive impairment.24 Chio and
colleagues26 have recently demonstrated that behavioural defi-
cits in ALS have a significant negative impact on caregivers’
quality of life and increase carer burden considerably. ALS
patients with executive dysfunction are also at higher risk of
falls, choking episodes and injuries. They show poorer compli-
ance with walking aids, percutaneous endoscopic gastrostomy
or radiologically inserted gastrostomy feeding tubes and other
safety devices.
It is likely that the concepts learnt from the palliative
management of other neurodegenerative conditions such as
advanced dementias can be applied in ALS. Insistence on non-
invasive ventilation and feeding tube placement in the presence
of significant behavioural and cognitive deficits can be inappro-
priate and should be carefully considered on an individual basis.
Recent data indicate that cognitive change must be considered
when approaching difficult decisions about management in the
later stages of the disease.27 However, the full implications of
ALS related cognitive decline on disease management remain to
be formally established.
Timing of ‘end of life discussions’
The optimal timing of end of life discussions in ALS is relatively
well defined in the international literature. ‘Trigger points’ for
discussion of end of life issues in ALS have been suggested by
a number of authors.11 28 These include the presence of patient
distress, the evolution of disease or the expressed desire of the
patient to discuss these issues (box 3).
Coordination of ALS care in different healthcare systems
International evidence based palliative models for ALS can be
developed by integration of successful regional initiatives and
identification of areas requiring further research. Although
access to palliative services, referral habits and coordination of
care vary considerably from country to country, common
themes and principles can be identified.
The Netherlands
The Dutch protocol for ALS management has been recently
published29 (box 4). Coordination of care is clearly defined in the
different phases of ALS. The protocol divides the disease into
diagnostic, rehabilitation and terminal phases and designates
a care coordinator for each. In the diagnostic phase, the
neurologist is the care coordinator; in the rehabilitation phase,
the consultant in rehabilitation medicine is the care coordinator;
while the general practitioner is the main care coordinator in the
terminal phase.
In a prospective Dutch study,3 patients treated by multidis-
ciplinary ALS care teams had a significantly better psychological
quality of life than those looked after by a general care group.
UK
A Neurological Conditions Policy Group was set up in 2004 by
the National Council for Palliative Care to evaluate good
practice examples and to identify effective service models. Gaps
in coordination between different services and an overlap
in their activities have been identified and a patient pathway
has been established.30 This describes specific indicators
for referral and introduces the concept of neuro-palliative-
rehabilitation. Based on this work, the Royal College of
Physicians, the National Council for Palliative Care and the
British Society of Rehabilitation Medicine have published
a national guideline on the interface between neurology, reha-
bilitation and palliative care.31 These guidelines have not yet
been fully implemented.
More recently, the Motor Neuron Disease Association has
produced the ‘year of care pathway ’32 which describes the
specific care and services that may be required with disease
progression.
USA
The current system in the USA is highly decentralised, and there
are no national guidelines. Palliative care is not nationally or
regionally coordinated but rather consists of a mix of different
services which differ by locality. For patients in the community
who do not attend multidisciplinary ALS clinics, the availability
of specialist palliative care is often limited. Hospice services are
organised locally, receive Medicare funding and are geared
towards end of life care. Palliative care takes place in the
patient’s homedapproximately 20% of patients receive hospice
services in an inpatient hospice facility.33 Home health agencies
provide short term care in the patient’s home for those patients
meeting specific eligibility requirements. Longer term care in the
home usually is overseen at the state level but administered
locally. Hours of care available and eligibility rules differ from
state to state and by the administrating agency.
Germany
The ALS guidelines of the German Neurological Society34
specifically suggest early referral to palliative care. However, in
practice, ALS patients are usually managed by their practising
Box 3 Triggers of end of life discussions in amyotrophic
lateral sclerosis
1. The patient opens the discussiondfor end of life information
and/or interventions (elicited or spontaneous, verbal or
non-verbal).
2. The presence of severe psychological, social or spiritual
distress or suffering
3. The presence of pain requiring high dosages of analgesic
medications
4. The presence of dysphagia requiring feeding tube
5. The presence of dyspnoea, symptoms of hypoventilation or
a forced vital capacity of 50% or less
6. Loss of function in two body regions (regions include bulbar,
arms and legs)
Box 4 The governing principles of the Dutch protocol for
amyotrophic lateral sclerosis management
1. Autonomy of the amyotrophic lateral sclerosis patient
2. Medical information should be given in time for adequate
decision making
3. The consultant in rehabilitation medicine should guarantee
optimal symptomatic rehabilitation care through to palliative
care in the terminal phase
4. Advance health directives should be repeatedly discussed
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neurologists and family practitioners. Access to palliative care
and hospice services occurs late in the course of the disease, if at
all. A network of neuromuscular centres in all major cities offers
tertiary care but not all patients are referred to these centres.
Although a nationwide network of specialist palliative home
care teams has recently been introduced, there is limited
collaboration between ALS centres and palliative care teams.
The role of the general practitioner in the terminal stages of
illness remains underdeveloped.35
Australia
A ‘map for integrated care’36 has been generated, showing the
role of key service providers in meeting specific patient needs at
different stages. The pathway of the Motor Neuron Disease
Association of England, Wales and Northern Ireland was iden-
tified as the framework that best describes the triggers for
referral, and the role and costs of service providers at specific
patient milestones.
Ireland
There is no established national care pathway nor are there
clearly defined triggers for activation of palliative care services
for ALS patients. A single multidisciplinary clinic, incorporating
palliative care, provides services to up to 80% of the ALS
population.4 ALS services are coordinated primarily by hospital
based neurologists, with direct referral to community based
palliative care services. Management in the later stages of the
disease is undertaken collaboratively between the specialist
hospital based services and community care, with limited
involvement of the general practitioner.
Measurement tools
Existing and proposed frameworks require rigorous auditing and
validation prior to implementation. Because palliative care shifts
the emphasis from disease modification to symptom manage-
ment, outcome measurements are primarily centred around
quality of life (QoL) rather than disease progression.
QoL is a concept of emotional, spiritual and physical well
being within the individual’s specific social, cultural and medical
context. Poor quality of life in ALS correlates with hopelessness
and lack of social support.37 Several studies38e40 in ALS have
demonstrated that QoL is independent of physical disability and
is frequently a function of complex psychosocial and existential/
spiritual factors. This evidence provides the rationale for a QoL
orientated palliative intervention in ALS and measurement of
QoL as a marker of successful multidomain palliative care
intervention.
Palliative measurement tools can be divided into assessment
scales and QoL measurement instruments.
Assessment tools: comprehensive palliative diagnosis
Formal palliative assessment is particularly important in
neurodegenerative disorders where underreporting of pain and
discomfort is not uncommon. A structured diagnostic palliative
approach identifies areas of distress and discomfort across
multiple domains: physical, emotional and spiritual.
The Memorial Symptom Assessment Scale, the Rotterdam
Symptom Checklist, the Edmonton Symptom Assessment Scale
and the Disability Distress Assessment Tool (DisDAT)41 repre-
sent some of the more widely used comprehensive assessment
tools with potential in non-neoplastic palliative medicine.
DisDAT may be of particular use in neurodegenerative
conditions such as ALS, as it is adapted for people with severe
communication difficulties. DisDAT documents the patient’s
own ‘vocabulary’ of distress signs and behaviours in a so-called
‘distress passport’.
Quality of life measures
QoL measurement in ALS is challenging due to communication
barriers. The use of generic instruments (Sickness Impact Profile/
SF-36 Health Survey) is limited in the assessment of QoL in ALS.
Memory and cognitive deficits may make testing even more
difficult. A number of observational rating scales have been
developed to overcome these challenges, many of them using
composite scores from carers and patients.
The Schedule for the Evaluation of Individualised Quality of Life-
Direct Weighting (SEIQoL-DW)39 is a useful tool in ALS, taking
individual value priorities into account. In the SEIQoL-DW,
patients rate their satisfaction in areas of life which are most
important to their QoL. The most relevant domains of QoL in
ALS are family, friends/social life, health and profession based on
the SEIQoL-DW studies.40 Longitudinal QoL studies in ALS
demonstrated that while health related QOL and functional
status showed relentless decline, the SEIQOL-DW total score
remained stable. Longitudinal studies also concluded that
patients’ QoL priorities change over time.
The Schedule for Meaning in Life Evaluation (SMiLE)42 is used
successfully in ALS where satisfaction is weighted against the
relevance of individually named domains. The most often high-
lighted areas ofMeaning of Life (MiL)43 in ALSwere family (82%),
partnership (61%), leisure activities (53%) and friends (39%).
The McGill QoL Questionnaire (MQoL)44 addresses five
domains: physical well being, physical symptoms, existential
well being, psychological symptoms and support through a 20
item questionnaire.
The ALS Specific QoL (ALSSQOL)45 rating instrument is based
on the MQoL Questionnaire and takes religiousness, spirituality
and psychological well being into account.
Evaluating QoL in the presence of cognitive impairment is
poorly studied in ALS. In a cross sectional QoL study46 of 31 ALS
patients, QoL scores correlated positively with social and
emotional support and correlated negatively with the presence
of everyday cognitive difficulties.
Several QoL scales have been developed for patients with
dementia and these could bemodified for use in patientswith ALS
and cognitive impairment. The Psychological Well-Being in
Cognitively Impaired Persons,47 the Dementia Care Mapping48
and the the Cornell-Brown Scale for Quality of Life inDementia49
are either observer rated assessment instruments or incorporate
the caregiver ’s perspective.
The use of these instruments in ALS is currently limited and
many of these tests were developed and validated for
Alzheimer ’s dementia rather than the frontotemporal cognitive
deficits typical of ALS. However, with the emerging evidence of
relatively high incidence of cognitive impairment in ALS, the
development of ALS specific QoL instruments for patients with
cognitive impairment is desirable.
Common themes of international initiatives
The appropriate timing of palliative intervention is essential and
confers important quality of life benefits. Despite cultural and
financial differences worldwide, a number of common principles
can be identified to ensure high quality palliative care in ALS
(box 5).
CONCLUSIONS
ALS management requires clear communication and cooperation
between different medical specialties, hospital and community
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based services. Patients and caregivers should be linked in early
to specialist palliative care services through multidisciplinary
ALS clinics. A dynamic, evidence based framework for inte-
grating palliative care into the management of ALS is urgently
required, and would be best achieved in the context of an
international consensus. Effective symptom management,
advance discussion of care preferences and continued caregiver
support are important governing principles. Disease specific
quality of life measurement tools should be applied to assess and
validate the role of palliative intervention in ALS. A successful
palliative model in ALS will in turn assist in the development of
palliative care models for other neurodegenerative conditions.
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